Holen Sie sich die Stockscreener-App
1.4776
4.91%
0.0526
Erasca Inc Aktie (ERAS) Neueste Nachrichten
BNP Paribas Financial Markets Makes New Investment in Erasca, Inc. (NASDAQ:ERAS) - Defense World
FDA clears Erasca’s new cancer drug applications By Investing.com - Investing.com South Africa
Erasca Receives US FDA Approval of ERAS-4001 Investigational New Drug Application for Solid Tumors - marketscreener.com
FDA clears Erasca’s new cancer drug applications - Investing.com Australia
Erasca, Inc. Announces Ind Clearance for Potential First-In-Class and Best-In-Class Pan-Kras Inhibitor Eras-4001 - marketscreener.com
Erasca (ERAS) Gains FDA Clearance for Innovative KRAS Inhibitor | ERAS Stock News - GuruFocus
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 - The Manila Times
Breakthrough: FDA Greenlights Novel Pan-KRAS Cancer Drug Targeting 2.2M Patients Worldwide - Stock Titan
ProShare Advisors LLC Raises Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Deutsche Bank AG Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Discover May 2025's Top Penny Stocks - simplywall.st
Bank of America Corp DE Has $4.88 Million Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Precision Oncology Pioneer Erasca Sets Major Investor Presentations at Jefferies and Goldman Sachs Conferences - Stock Titan
Erasca, Inc. (NASDAQ:ERAS) Shares Sold by Janus Henderson Group PLC - Defense World
D. E. Shaw & Co. Inc. Has $927,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Northern Trust Corp Boosts Stock Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Given Average Rating of “Buy” by Analysts - Defense World
Erasca Inc (NASDAQ: ERAS) Could Pass $5 In One Year Stock Forecast - Stocksregister
Price T Rowe Associates Inc. MD Buys 10,899 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
HC Wainwright Has Positive Forecast for Erasca Q2 Earnings - Defense World
Erasca (ERAS) Target Price Adjusted by Guggenheim Analyst | ERAS Stock News - GuruFocus
FDA clears Erasca’s new cancer drug ERAS-0015 By Investing.com - Investing.com India
Erasca (ERAS) Advances RAS-Targeting Therapies with New Clinical Developments | ERAS Stock News - GuruFocus
Erasca Reports First Quarter 2025 Business Updates and Financial Results - The Manila Times
Erasca, Inc. Advances RAS-Targeting Pipeline with IND Clearances and Extended Cash Runway - Nasdaq
Erasca Advances Two Novel Cancer Drugs to Clinic, Secures 3-Year Cash Runway with $411M - Stock Titan
Erasca Seeks Partner for Naporafenib to Extend Cash Runway - marketscreener.com
Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | - GuruFocus
Erasca (ERAS) Advances RAS-Targeting Drugs with FDA Clearance | ERAS Stock News - GuruFocus
FDA clears Erasca’s new cancer drug ERAS-0015 - Investing.com
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway - The Manila Times
Dimensional Fund Advisors LP Increases Position in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Hsbc Holdings PLC Purchases 10,458 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. (NASDAQ:ERAS) Shares Bought by Tower Research Capital LLC TRC - Defense World
Erasca (ERAS) Expected to Announce Quarterly Earnings on Wednesday - Defense World
MetLife Investment Management LLC Has $283,000 Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca to Present at the Bank of America Securities Health Care Conference - TradingView
Recurrent Glioblastoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Invesco Ltd. Acquires 11,290 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Barclays PLC Boosts Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Wells Fargo & Company MN Sells 73,262 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
HC Wainwright Reaffirms Buy Rating for Erasca (NASDAQ:ERAS) - Defense World
Holdings of Erasca Inc (ERAS) are aligned with the stars - Sete News
Analyze Erasca Inc (NASDAQ: ERAS) Before Investing. - Stocksregister
Erasca Inc (ERAS)’s stock price range in the last year - uspostnews.com
Legal & General Group Plc Buys 64,574 Shares of Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca (ERAS) Showcases Innovative RAS-Targeting Treatments at C - GuruFocus
Erasca presents new RAS-targeting franchise data at AACR meeting - TipRanks
XTX Topco Ltd Purchases Shares of 55,361 Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting - The Manila Times
New Cancer Drug Data: Erasca's RAS Inhibitors Show Best-in-Class Potential at AACR 2025 - Stock Titan
Erasca Inc (NASDAQ: ERAS) Shares Are Down -44.22% Year To Date. - Marketing Sentinel
Checking in on Erasca Inc (ERAS) after recent insiders movement - knoxdaily.com
Erasca (ERAS) Showcases Innovative RAS-Targeting Treatments at Cancer Research Event | ERAS Stock News - GuruFocus
Absci Corp (NASDAQ: ABSI): The Stock For Success Over The Next Few Months - Marketing Sentinel
Erasca, Inc: Carving A Different Niche In RAS Signaling (NASDAQ:ERAS) - Seeking Alpha
0.00%
2.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):